<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03933748</url>
  </required_header>
  <id_info>
    <org_study_id>2019_Teicoplanin_001</org_study_id>
    <nct_id>NCT03933748</nct_id>
  </id_info>
  <brief_title>Therapeutic Drug Monitoring of Teicoplanin in Children</brief_title>
  <official_title>Therapeutic Drug Monitoring of Teicoplanin in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Qianfoshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Qinghai University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jinan children's hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yantai Yuhuangding Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jinan Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaocheng People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weifang People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Linyi People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated hospital of jining medical college</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weihai maternal and child health care hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the therapeutic drug monitoring of teicoplanin is carried out among children
      to obtain the drug concentration, clinical efficacy and safety data of children patients in
      different gender and age groups. Then we analyze the relationship between blood drug
      concentration and efficacy and safety, and provide recommendations for the treatment window
      of teicoplanin in Chinese children.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma drug concentration</measure>
    <time_frame>Through study completion, an average of 14 days</time_frame>
    <description>To detect the plasma concentrations of teicoplanin at therapeutic drug monitoring (TDM).</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Bacterial Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teicoplanin-PMMA</intervention_name>
    <description>Therapeutic drug monitoring of teicoplanin</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children with gram-positive coccus infection
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Teicoplanin was administered intravenously;

          -  Teicoplanin was used for therapeutic purposes;

          -  Age:≤18 years;

          -  Clinician confirms and plans to diagnose the patient with gram-positive coccus
             infection;

          -  Patients with therapeutic concentration monitoring of teicoplanin.

        Exclusion Criteria:

          -  Teicoplanin was administered non-intravenously;

          -  Teicoplanin was used for prophylactic purposes;

          -  Patients without therapeutic concentration monitoring of teicoplanin;

          -  Patients who die within 24 hours of the use of teicoplanin；

          -  The blood concentrations of the patient was not approved by the quality control
             center.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wei Zhao, Ph.D</last_name>
    <phone>86053188383308</phone>
    <email>zhao4wei2@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shandong Provincial Qianfoshan Hospital</name>
      <address>
        <city>Ji'nan</city>
        <state>Shandong</state>
        <zip>250014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Zhao, Ph.D</last_name>
      <phone>86053188383308</phone>
      <email>zhao4wei2@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 24, 2019</study_first_submitted>
  <study_first_submitted_qc>April 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>April 11, 2020</last_update_submitted>
  <last_update_submitted_qc>April 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Wei Zhao</investigator_full_name>
    <investigator_title>Head of department of clinical pharmacy and pharmacology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teicoplanin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

